No Data
No Data
BeyondSpring Plinabulin, Merck Keytruda Combo Shows Promise in NSCLC
BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024
BeyondSpring Presents Efficacy/Safety Results From a Phase 2 Study of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024
BeyondSpring Presents Final Phase 3 Results For Plinabulin In 2L/3L NSCLC At ISLAC 2024, With Concurrent Publication In The Lancet Respiratory Medicine
Express News | Beyondspring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During Esmo Congress 2024 Showcasing Its Lead Anti-Cancer Asset, Plinabulin
Is BeyondSpring (NASDAQ:BYSI) In A Good Position To Invest In Growth?
No Data
No Data